{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:31:39Z","timestamp":1790699499583,"version":"4.1.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ekir.2023.11.026","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T12:54:25Z","timestamp":1701435265000},"page":"203-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Novel Treatment Paradigms: Primary IgA Nephropathy"],"prefix":"10.1016","volume":"9","author":[{"given":"Haresh","family":"Selvaskandan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Barratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee Kay","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2023.11.026_bib1","first-page":"694","article-title":"[Intercapillary deposits of IgA-IgG]","volume":"74","author":"Berger","year":"1968","journal-title":"J\u00a0Urol Nephrol (Paris)"},{"key":"10.1016\/j.ekir.2023.11.026_bib2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/ki.1995.50","article-title":"IgA nephropathy","volume":"47","author":"Galla","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2023.11.026_bib3","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1681\/ASN.2007050526","article-title":"Remission of proteinuria improves prognosis in IgA nephropathy","volume":"18","author":"Reich","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.11.026_bib4","first-page":"355","article-title":"Long-term follow-up of IgA mesangial nephropathy: clinico-histological study in 374 patients","volume":"7","author":"D\u2019Amico","year":"1987","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.ekir.2023.11.026_bib5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ekir.2017.08.008","article-title":"Life expectancy for patients from the Southeastern United States with IgA nephropathy","volume":"3","author":"Hastings","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2023.11.026_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0091756","article-title":"Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan","volume":"9","author":"Moriyama","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2023.11.026_bib7","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.11.026_bib8","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1681\/ASN.2018101017","article-title":"Mortality in IgA nephropathy: a nationwide population-based cohort study","volume":"30","author":"Jarrick","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.11.026_bib9","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1053\/j.ajkd.2013.04.019","article-title":"Mortality in patients with IgA nephropathy","volume":"62","author":"Knoop","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2023.11.026_bib10","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2215\/CJN.00910121","article-title":"Recurrence of igA nephropathy after kidney transplantation in adults","volume":"16","author":"Uffing","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.11.026_bib11","first-page":"209","article-title":"Clinical practice guideline for glomerulonephritis","volume":"2","author":"KDIGO","year":"2012","journal-title":"Kidney Int Suppl (2011)"},{"key":"10.1016\/j.ekir.2023.11.026_bib12","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2215\/CJN.08600718","article-title":"Proteinuria reduction as a surrogate end point in trials of IgA nephropathy","volume":"14","author":"Thompson","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.11.026_bib13","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1001\/jamainternmed.2019.0600","article-title":"Evaluating a new international risk-prediction tool in IgA nephropathy","volume":"179","author":"Barbour","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ekir.2023.11.026_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.572754","article-title":"Monitoring immune responses in IgA nephropathy: biomarkers to guide management","volume":"11","author":"Selvaskandan","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2023.11.026_bib15","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2023.11.026_bib16","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2023.11.026_bib17","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2023.11.026_bib18","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/j.1523-1755.2004.00588.x","article-title":"Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study","volume":"65","author":"Maes","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2023.11.026_bib19","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1053\/j.ajkd.2015.06.013","article-title":"Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy","volume":"66","author":"Hogg","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2023.11.026_bib20","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1093\/ndt\/gfh974","article-title":"Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial","volume":"20","author":"Frisch","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2023.11.026_bib21","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1523-1755.2005.00460.x","article-title":"Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy","volume":"68","author":"Tang","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2023.11.026_bib22","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.54054","article-title":"Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial","volume":"6","author":"Hou","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ekir.2023.11.026_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.ajkd.2019.01.026","article-title":"Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial","volume":"74","author":"Liu","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2023.11.026_bib24","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10157-019-01700-1","article-title":"New strategies and perspectives on managing IgA nephropathy","volume":"23","author":"Selvaskandan","year":"2019","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.ekir.2023.11.026_bib25","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2023.11.026_bib26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2023.11.026_bib27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A\u00a0pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2023.11.026_bib28","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.kint.2021.04.002","article-title":"SGLT-2 inhibition in IgA nephropathy: the new standard of care?","volume":"100","author":"Barratt","year":"2021","journal-title":"Kidney Int"},{"issue":"24","key":"10.1016\/j.ekir.2023.11.026_bib29","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1016\/j.febslet.2015.10.033","article-title":"Increased miR-374b promotes cell proliferation and the production of aberrant glycosylated IgA1 in B cells of IgA nephropathy","volume":"589","author":"Hu","year":"2015","journal-title":"FEBS Lett"},{"key":"10.1016\/j.ekir.2023.11.026_bib30","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/ndt\/gfm781","article-title":"External suppression causes the low expression of the Cosmc gene in IgA nephropathy","volume":"23","author":"Qin","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2023.11.026_bib31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12882-019-1675-5","article-title":"C1GALT1 expression is associated with galactosylation of IgA1 in peripheral B lymphocyte in immunoglobulin A nephropathy","volume":"21","author":"Xing","year":"2020","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2023.11.026_bib32","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1681\/ASN.2011060567","article-title":"Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy","volume":"23","author":"Serino","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.11.026_bib33","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1681\/ASN.2016091043","article-title":"Galactosylation of IgA1 is associated with common variation in C1GALT1","volume":"28","author":"Gale","year":"2017","journal-title":"JASN: ASN"},{"key":"10.1016\/j.ekir.2023.11.026_bib34","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.molimm.2019.07.017","article-title":"The role of complement in IgA nephropathy","volume":"114","author":"Tortajada","year":"2019","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ekir.2023.11.026_bib35","first-page":"8","article-title":"Immunological drivers of IgA nephropathy: exploring the mucosa-kidney link","volume":"49","author":"Selvaskandan","year":"2022","journal-title":"J\u00a0Immunogenet"},{"key":"10.1016\/j.ekir.2023.11.026_bib36","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.kint.2021.04.026","article-title":"Nasal-associated lymphoid tissue is the major induction site for nephritogenic IgA in murine IgA nephropathy","volume":"100","author":"Kano","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2023.11.026_bib37","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1365-2249.2008.03855.x","article-title":"CpG-oligodeoxynucleotides stimulate immunoglobulin A secretion in intestinal mucosal B cells","volume":"155","author":"Blaas","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ekir.2023.11.026_bib38","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.4049\/jimmunol.1000702","article-title":"Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines","volume":"186","author":"Kuznik","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.ekir.2023.11.026_bib39","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1038\/s41467-022-31761-y","article-title":"Dietary protein increases T-cell-independent sIgA production through changes in gut microbiota-derived extracellular vesicles","volume":"13","author":"Tan","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ekir.2023.11.026_bib40","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/ni829","article-title":"DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL","volume":"3","author":"Litinskiy","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ekir.2023.11.026_bib41","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1074-7613(02)00398-9","article-title":"Dendritic cells, BAFF, and APRIL: innate players in adaptive antibody responses","volume":"17","author":"MacLennan","year":"2002","journal-title":"Immunity"},{"key":"10.1016\/j.ekir.2023.11.026_bib42","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1146\/annurev.immunol.26.021607.090248","article-title":"Mechanism and regulation of class switch recombination","volume":"26","author":"Stavnezer","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.ekir.2023.11.026_bib43","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1093\/ndt\/gfr052","article-title":"New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria","volume":"26","author":"Smerud","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"suppl 3","key":"10.1016\/j.ekir.2023.11.026_bib44","article-title":"FC050: Nefecon\u00ae selectively modifies the composition of circulating immune complexes in IGA nephropathy","volume":"37","author":"Molyneux","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"suppl 3","key":"10.1016\/j.ekir.2023.11.026_bib45","article-title":"P0344NEFECON\u00ae (budesonide) selectively reduces circulating levels of BAFF (BLYS) and soluble BCMA and TACI in IGA nephropathy","volume":"35","author":"Molyneux","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2023.11.026_bib46","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial","volume":"389","author":"Fellstr\u00f6m","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2023.11.026_bib47","doi-asserted-by":"crossref","first-page":"S361","DOI":"10.1016\/j.ekir.2021.03.868","article-title":"POS-830 NEFECON FOR THE TREATMENT OF IgA NEPHROPATHY IN PATIENTS AT RISK OF PROGRESSING TO END-STAGE RENAL DISEASE: the NEFIGARD PHASE 3 TRIAL RESULTS","volume":"6","author":"BARRATT","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2023.11.026_bib48","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2023.11.026_bib49","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1146\/annurev.pharmtox.41.1.851","article-title":"Endothelin system: the double-edged sword in health and disease","volume":"41","author":"Kedzierski","year":"2001","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.ekir.2023.11.026_bib51","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1159\/000188912","article-title":"Effect of a specific endothelin receptor A antagonist on glomerulonephritis of ddY mice with IgA nephropathy","volume":"72","author":"Nakamura","year":"1996","journal-title":"Nephron"},{"key":"10.1016\/j.ekir.2023.11.026_bib52","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14712\/fb2007053010027","article-title":"The influence of three endothelin-1 polymorphisms on the progression of IgA nephropathy","volume":"53","author":"Maixnerov\u00e1","year":"2007","journal-title":"Folia Biol"},{"key":"10.1016\/j.ekir.2023.11.026_bib53","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1681\/ASN.V12112321","article-title":"Renal endothelin-1 and endothelin receptor type B expression in glomerular diseases with proteinuria","volume":"12","author":"LEHRKE","year":"2001","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.11.026_bib54","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","article-title":"Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial","volume":"401","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2023.11.026_bib55","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Perkovic","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2023.11.026_bib56","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of Sparsentan Versus Irbesartan in Patients With IgA Nephropathy (PROTECT): 2-Year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Brad","year":"2023","journal-title":"Lancet"},{"issue":"suppl 3","key":"10.1016\/j.ekir.2023.11.026_bib57","article-title":"FC052: atrasentan for the treatment of IGA nephropathy: interim results from the affinity study","volume":"37","author":"Kim","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2023.11.026_bib59","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A\u00a0randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction","volume":"28","author":"Lafayette","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.11.026_bib60","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1182\/blood-2010-01-266536","article-title":"Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab","volume":"116","author":"Mei","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2023.11.026_bib61","first-page":"683","article-title":"Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features","volume":"26","author":"Xin","year":"2013","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.ekir.2023.11.026_bib62","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/ndt\/gfaa264","article-title":"High levels of gut-homing immunoglobulin A+ B lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients","volume":"36","author":"Sallustio","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2023.11.026_bib63","doi-asserted-by":"crossref","first-page":"e3099","DOI":"10.1097\/MD.0000000000003099","article-title":"Increased APRIL expression induces IgA1 aberrant glycosylation in IgA nephropathy","volume":"95","author":"Zhai","year":"2016","journal-title":"Med (Baltim)"},{"key":"10.1016\/j.ekir.2023.11.026_bib64","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3118","article-title":"Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens","volume":"46","author":"Kiryluk","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.ekir.2023.11.026_bib65","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cellimm.2006.08.002","article-title":"BAFF induces a hyper-IgA syndrome in the intestinal lamina propria concomitant with IgA deposition in the kidney independent of LIGHT","volume":"241","author":"McCarthy","year":"2006","journal-title":"Cell Immunol"},{"key":"10.1016\/j.ekir.2023.11.026_bib66","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1172\/JCI45563","article-title":"Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy","volume":"121","author":"McCarthy","year":"2011","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ekir.2023.11.026_bib67","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/j.ekir.2023.02.169","article-title":"WCN23-0684 interim biomarker analysis from a randomized, double-blind, placebo-controlled, PHASE 2 trial of sibeprenlimab (VIS649) in participants with immunoglobulin A nephropathy","volume":"8","author":"Chan","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2023.11.026_bib68","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A\u00a0Phase 2 trial of sibeprenlimab in patients with IgA nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"Supplement_1","key":"10.1016\/j.ekir.2023.11.026_bib69","doi-asserted-by":"crossref","first-page":"FC040","DOI":"10.1093\/ndt\/gfab117.004","article-title":"Interim results of PHASE 1 AND 2 trials to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of BION-1301 in patients with IGA nephropathy","volume":"36","author":"Barratt","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2023.11.026_bib70","article-title":"36-week Efficacy & Safety of atacicept 150 mg in the ORIGIN Randomized, Double-blind, Placebo-controlled Phase 2b study in IgAN and Persistent Proteinuria","author":"Lafayette","year":"2023","journal-title":"60th ERA Congress"},{"key":"10.1016\/j.ekir.2023.11.026_bib71","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized Phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria","volume":"8","author":"Lv","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2023.11.026_bib72","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1093\/ndt\/gfac296","article-title":"The role of complement in glomerulonephritis\u2014are novel therapies ready for prime time?","volume":"38","author":"Cheung","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2023.11.026_bib73","doi-asserted-by":"crossref","first-page":"S236","DOI":"10.1016\/j.ekir.2022.01.577","article-title":"POS-546 EFFICACY AND SAFETY OF IPTACOPAN IN IgA NEPHROPATHY: RESULTS OF A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 2 STUDY AT 6 months","volume":"7","author":"Barratt","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2023.11.026_bib74","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.kint.2023.09.027","article-title":"Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy","volume":"105","author":"Zhang","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2023.11.026_bib75","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.ekir.2023.01.041","article-title":"Targeting the alternative complement pathway with iptacopan to treat IgA nephropathy: design and rationale of the APPLAUSE-IgAN study","volume":"8","author":"Rizk","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2023.11.026_bib76","series-title":"An Exploratory Trial of an Investigational RNA Therapeutic","author":"Barbour","year":"2022"},{"key":"10.1016\/j.ekir.2023.11.026_bib77","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.ekir.2020.08.003","article-title":"Safety, tolerability and efficacy of narsoplimab, a novel MASP-2 inhibitor for the treatment of IgA nephropathy","volume":"5","author":"Lafayette","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2023.11.026_bib79","article-title":"Exploratory Results From the Phase 2 Study of Cemdisiran in Patients With IgA Nephropathy","author":"Barratt","year":"2022","journal-title":"ASN Kidney Week"},{"key":"10.1016\/j.ekir.2023.11.026_bib80","article-title":"Efficacy and safety of ravulizumab in a Phase 2 randomized controlled trial in IgA nephropathy","author":"Barratt","year":"2023","journal-title":"ASN Kidney Week"},{"issue":"suppl 3","key":"10.1016\/j.ekir.2023.11.026_bib81","article-title":"TO012C5A receptor inhibitor avacopan in IGA nephropathy study","volume":"32","author":"Bruchfeld","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2023.11.026_bib82","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1093\/ndt\/gfad146","article-title":"IgA nephropathy in adults - Treatment Standard","volume":"38","author":"Gleeson","year":"2023","journal-title":"Nephrol Dial Transplant"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024923016157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024923016157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:48:07Z","timestamp":1762832887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024923016157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":79,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2468024923016157"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2023.11.026","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Treatment Paradigms: Primary IgA Nephropathy","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2023.11.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}